A Common Rule for Resection of Glioblastoma in the Molecular Era
Menée à partir de données portant sur 967 patients atteints d'un glioblastome, cette étude évalue, en fonction des caractéristiques moléculaires de la tumeur (présence d'une mutation sur le gène 1 ou 2 de l'isocitratedéshydrogénase), l'association entre l'étendue maximale de la résection de la tumeur et la survie globale
In this issue of JAMA Oncology, Molinaro et al retrospectively assess the value of aggressive resection of glioblastoma (GBM) across molecular subtypes in a timely analysis. Both the large number of participants and the use of a significant development cohort and a multicenter validation cohort add strength to the findings.Glioblastoma is the most common type of primary brain tumor and is also the most difficult to treat. Despite modern multimodal therapy including resection, radiotherapy, chemotherapy, and alternating electric fields, GBM remains one of the most aggressive and lethal cancers, with 5-year survival rates of less than 10%.
JAMA Oncology , commentaire, 2019